**Core Concept**
Tacrolimus is a calcineurin inhibitor used primarily in organ transplantation to prevent graft rejection. It works by suppressing T-cell activation through inhibition of calcineurin, thereby reducing cytokine production. It is not an antibiotic and has significant nephrotoxicity, especially when used long-term.

**Why the Correct Answer is Right**
Option B is incorrect because tacrolimus is **not safe** to administer with nephrotoxic drugs. Both tacrolimus and many nephrotoxic agents (like aminoglycosides, cyclosporine, or contrast media) can cause renal dysfunction. Their combined use increases the risk of acute kidney injury due to additive nephrotoxic effects. This interaction is clinically significant and requires careful monitoring of renal function.

**Why Each Wrong Option is Incorrect**
Option A: Tacrolimus is **not** a macrolide antibiotic; it is a **calcineurin inhibitor**. Macrolides (e.g., erythromycin) are antibiotics that inhibit bacterial protein synthesis. This statement is factually wrong and misleading.
Option C: Glucose intolerance and diabetes mellitus are well-documented side effects of tacrolimus due to insulin resistance and reduced glucose uptake in peripheral tissues.
Option D: Tacrolimus is a cornerstone in **post-transplant prophylaxis** against acute rejection, especially in liver, kidney, and heart transplants.

**Clinical Pearl / High-Yield Fact**
Tacrolimus has a narrow therapeutic window and requires frequent monitoring of blood levels. It should **never** be combined with other nephrotoxic agents without close renal function assessment. Always check for drug interactions before co-administration.

✓ Correct Answer: B. It can be safely administered with any nephrotoxic drug